Rationale for Categorizing Hydrocodone Combination Products as Schedule III

Published Online: Monday, January 20, 2014
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, discusses why hydrocodone combination products were categorized as Schedule III in the first place.
 
This is the fifth in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Latest Articles
Pharmacists know that a cough can be triggered by many stimuli.
A Super Bowl 50 commercial may be encouraging patients to seek help for their constipation.
The FDA has accepted for review Otsuka and Lundbeck’s supplemental new drug application for a label update to brexipiprazole.
Pharmacists might be surprised to learn that Pinterest is a hotbed for anti-vaccine sentiment.
Latest Issues
$auto_registration$